Corporate Releases
LONDON, 14 November 2008 – Optos plc (LSE: OPTS), the leading medical retinal imaging technology company, is pleased to announce that Mr Roy Davis, the former Chief Executive Officer of Gyrus Group plc, has been appointed as Chief Executive Officer with effect from 17 November 2008. Mr Thomas W. Butts has left the Company to pursue other interests. He leaves with the best wishes of the Board.
LONDON, UK, 30 September 2008 – Optos plc (LSE: OPTS), the leading medical retinal imaging technology company, is today issuing a pre-close trading statement for the financial year ending 30 September 2008, ahead of the Group’s preliminary results announcement on 4 December 2008.
LONDON, UK, 31 July 2008 - Optos plc (LSE: OPTS), a leading medical technology company for the design, development, manufacturing and marketing of retinal imaging devices, is today publishing its Interim Management Statement (IMS) as required by the UK Listing Authority Disclosure and Transparency Rules covering the nine month period ended 30 June 2008.
LONDON, UK, 23 May 2008 - Optos plc (LSE: OPTS), a leading medical technology company for the design, development, manufacturing and marketing of retinal imaging devices, hosted an analyst and investor information update in London yesterday.
LONDON, UK, 21 May 2008 – Optos plc (LSE: OPTS), a leading medical technology company for the design, development, manufacturing and marketing of retinal imaging devices, is today announcing its interim results covering the six-month period ended 31 March 2008.
LONDON, UK, 13 May 2008 – Optos plc (LSE: OPTS), a leading medical technology company for the design, development, manufacturing and marketing of retinal imaging devices, is today announcing that it has launched an upgraded version of its proprietary retinal imaging software designed to support practitioners in their clinical mandate and improve their practice management capabilities.
LONDON, UK, 07 May 2008 – Optos plc (LSE: OPTS), a leading medical technology company for the design, development, manufacturing and marketing of retinal imaging devices, is today announcing that it has been named by the European Commission and European Patent Office (EPO) as European Inventor of the Year 2008 in the SME and Research category in recognition of the Company’s proprietary scanning...
LONDON, UK, 02 May 2008 – Optos plc (LSE: OPTS), a leading medical technology company for the design, development, manufacturing and marketing of retinal imaging devices, is today announcing that the Company’s P200MA device has been used in a major diabetic research study that has revealed new findings in peripheral retinal neovascularisation. Specifically, that peripheral retinal vascular...
LONDON, UK, 1 May 2008 – Optos plc (LSE: OPTS), a leading medical technology company for the design, development, manufacturing and marketing of retinal imaging devices, is today announcing that its P200 device has supported a team of scientists led by The Children’s Hospital of Philadelphia (CHOP) and The University of Pennsylvania School of Medicine in a clinical trial where gene therapy has...
LONDON, UK, 16 April 2008 – Optos plc (LSE: OPTS), a leading medical technology company for the design, development, manufacturing and marketing of retinal imaging devices, is today announcing that it has launched a new retinal imaging device - the P200C. The device is designed to meet the need for more exacting clinical imaging capabilities and standards within the ophthalmology market and at...
LONDON, UK, 31 March 2008 – Optos plc (LSE: OPTS), a leading medical technology company for the design, development, manufacturing and marketing of retinal imaging devices, is today issuing the following trading statement ahead of the Group’s interim results for the six-month period ended 31 March 2008, which will be announced on 21 May 2008.
LONDON, UK, 28 March 2008 – Optos plc (LSE: OPTS), a leading medical technology company for the design, development, manufacturing and marketing of retinal imaging devices, today announced that the Company’s P200 device has been added to the Wal-Mart Stores Inc. Advanced Instrument Program.
LONDON, UK, 29 February 2008 – Optos plc (LSE: OPTS), a leading medical technology company for the design, development, manufacturing and marketing of retinal imaging devices, today announced that all of the proposed resolutions set out in the Notice of AGM were passed by shareholders at the Company’s Annual General Meeting held on 28 February 2008.
LONDON, UK, 28 February 2008 – Optos plc (LSE: OPTS), a leading medical technology company for the design, development, manufacturing and marketing of retinal imaging devices, is today holding its Annual General Meeting (the “AGM”) commencing at 11h00GMT at the offices of Maclay Murray & Spens LLP, One London Wall, London, EC2Y 5AB. Management will be making a presentation to shareholders. The...
LONDON, UK, 13 February 2008 - In accordance with Prospectus Rule 5.2, Optos plc is pleased to provide its Annual Information Update relating to information that has been published and made publicly available between 24 January 2007, the date of the Company’s last Annual Information Update, and 13 February 2008.
Submitted by: John McNeil, Company Secretary
LONDON, UK, 04 February 2008 – Optos plc (LSE: OPTS), a leading medical technology company for the design, development, manufacturing and marketing of retinal imaging devices, today confirmed the following key announcement dates for the remainder of the financial year ending 30 September 2008.
LONDON, UK, 29 January 2008 – Optos plc (LSE: OPTS), a leading medical technology company for the design, development, manufacturing and marketing of retinal imaging devices, is announcing that its Annual Report and Accounts for the year ended 30 September 2007, Notice of AGM and Form of Proxy for the Annual General Meeting being held on 28 February 2008 are being mailed to shareholders today....
LONDON, UK, 28 January 2008 – Optos plc (LSE: OPTS), a leading medical technology company for the design, development, manufacturing and marketing of retinal imaging devices, is today publishing its first Interim Management Statement (IMS) as required by the UK Listing Authority Disclosure and Transparency Rules for the three month period ended 31 December 2007 (the “period”) of the financial...
LONDON, UK, 29 November 2007 – Optos plc (LSE: OPTS), a leading medical technology company for the design, development, manufacturing and marketing of retinal imaging devices, today announced that it has received the Technology Innovation of the Year Award at the 2007 techMARK Awards.
LONDON, 29 November 2007 – Optos plc (LSE: OPTS), a leading medical technology company for the design, development, manufacturing and marketing of retinal imaging devices, today announced its preliminary results for the year ended 30 September 2007. All numbers are denominated in $USD which is the Company’s reporting currency and prepared under International Financial Reporting Standards (IFRS).
LONDON, 9 November 2007 – Optos plc (LSE: OPTS), a leading medical technology company for the design, development, manufacturing and marketing of retinal imaging devices, will announce its preliminary results for the year ended 30 September 2007 on Thursday 29 November 2007.
LONDON, UK, 10 October 2007 – Optos plc (LSE: OPTS), a leading medical technology company for the design, development, manufacturing and marketing of retinal imaging devices, today announced plans to expand into four new European markets - France, Spain, Switzerland, Norway - following the completion of market research and trial placements of the Company’s retinal scanning devices.
LONDON, UK, 27 September 2007 – Optos plc (LSE: OPTS), a leading medical technology company for the design, development, manufacturing and marketing of retinal imaging devices, is today issuing the following trading update ahead of the Group’s preliminary results for the year ended 30 September 2007, which will be announced on 29 November 2007.
LONDON, UK, 31 August 2007 – Optos plc (LSE: OPTS), a leading medical technology company for the design, development, manufacturing and marketing of retinal imaging devices, today announced that it will be presenting at the upcoming Goldman Sachs European Medtech & Healthcare Services Conference in London, UK, on 05-06 September 2007.
LONDON, UK, 02 AUGUST 2007 – Optos plc (LSE: OPTS), a leading medical technology company for the design, development, manufacturing and marketing of retinal imaging devices, today announced that the Company’s P200 device has been installed at the University of Virginia (UVa) Health System to ensure that the 2, 000 diabetic patients served by the outpatient clinic receive annual retinal exams...
LONDON, UK, 01 AUGUST 2007 – Optos plc (LSE: OPTS), a leading medical technology company for the design, development, manufacturing and marketing of retinal imaging devices, today announced the appointment of Saad H. Hammad, Chief Commercial Officer of easyJet plc, and Rosalyn S. Wilton, Chairman of Ipreo Holdings LLC, to the Board as non-executive directors of the Company with effect from 1...
LONDON, 30 May 2007 - Optos plc (LSE: OPTS) received notification on 30 May 2007 from Douglas C. Anderson, a director of the Company, that on 30 May 2007 Crombie Anderson & Associates Limited, a privately held company of which Mr Anderson is the majority shareholder, sold 900, 000 existing ordinary shares of £0.02 each in the capital of the Company at £2.50 per share. Crombie Anderson &...
LONDON, 30 May 2007 - Optos plc (LSE:OPTS) today announced that on 29 May 2007 it made a grant of awards and options over the Company’s ordinary shares of £0.02 each under the Performance Share Plan 2007 (“PSP”) and Share Option Plan 2007 (“SOP”) to Executive Directors and Persons Discharging Managerial Responsibilities (“PDMR”) as detailed in the table below.
LONDON, 24 May 2007 – Optos plc (LSE: OPTS), a leading medical technology company for the design, development, manufacturing and marketing of retinal imaging devices, today announced its interim results for the six months ended 31 March 2007. All numbers are denominated in $USD which is the Company’s reporting currency and prepared under International Financial Reporting Standards (IFRS).
LONDON, UK, 15 May 2007 – Optos plc (LSE: OPTS), a leading medical technology company for the design, development, manufacturing and marketing of retinal imaging devices, today announced that it has released the latest version of its proprietary software - V2® Vantage. The leading new features are designed to assist healthcare practitioners in capturing and reviewing the optomap® Retinal Exam...
LONDON, UK, 11 May 2007 – Optos plc (LSE: OPTS), a leading medical technology company for the design, development, manufacturing and marketing of retinal imaging devices, has received the 2007 Queen’s Award for Enterprise: International Trade.
LONDON, UK, 3 May 2007 – Optos plc (LSE: OPTS), a leading medical technology company for the design, development, manufacturing and marketing of retinal imaging devices, has received the 2007 Scotland plc Award for Innovation. The Award, sponsored by Oracle, recognises the efforts of companies in the identification, development and launch of new concepts capable of enhancing business performance,...
LONDON, UK, 23 April 2007 – Optos plc (LSE: OPTS), a leading medical technology company for the design, development, manufacturing and marketing of retinal imaging devices, today announced that Ian H. Stevens has decided to leave the Company following the completion of his international assignment in North America, with effect from 30 April 2007. Mr Stevens will also step down from the Board. Tom...
LONDON, UK, 04 April 2007 – Optos plc (LSE: OPTS), a leading medical technology company for the design, development, manufacturing and marketing of retinal imaging devices, is today providing notification that it will announce its interim results for the six month period ended 31 March 2007 on 24 May 2007.
During the first half sales growth continued at a strong rate in the Company’s North...
LONDON, UK, 29 March 2007 – Optos plc (LSE: OPTS), a leading medical technology company for the design, development, manufacturing and marketing of retinal imaging devices, today announced it has agreed with Pearle Vision to install its Panoramic200 Scanning Laser Ophthalmoscope (P200) device, which generates the optomap® Retinal Exam, in certain Pearle Vision locations throughout North America.
LONDON, UK, 07 February 2007 – Optos plc (LSE: OPTS), a leading medical technology company for the design, development, manufacturing and marketing of retinal imaging devices, today announced that its P200 devices, which are currently installed in eye and health care practices in the USA, Canada, UK and Germany, have now performed 10 million optomap® Retinal Exams since the first was performed in...
Edinburgh, UK - 31 January 2007: Optos plc (LSE:OPTS), a leading medical technology company, announces that at the Annual General Meeting of Optos plc (the 'AGM') held earlier today all of the proposed resolutions were passed.
LONDON, UK, 24 January 2007 – Optos plc (LSE: OPTS), a leading medical technology company for the design, development, manufacturing and marketing of retinal imaging devices, is today providing an update for the first quarter of the financial year ending 30 September 2007.
DUNFERMLINE, UK, 8 January 2007 – Optos plc (LSE: OPTS), today announced that its Annual Report and Accounts for the year ended 30 September 2006, its AGM Notice and Proxy Form for the 2007 Annual General Meeting was posted to shareholders on Friday 5 January 2007.
DUNFERMLINE, UK, 18 December 2006 – Optos plc (LSE: OPTS), a leading medical technology company for the design, development, manufacturing and marketing of retinal imaging devices today announced that it has appointed Thomas W. Butts as Chief Executive Officer and a member of the Board of Directors, with immediate effect.
Optos plc (LSE: OPTS), a leading medical technology company for the design, development, manufacturing and marketing of retinal imaging devices, today announced its preliminary results for the year ended 30 September 2006. All numbers are denominated in US dollars which is the Company’s reporting currency and prepared under International Financial Reporting Standards (IFRS).
LONDON, UK, 25 October 2006 – Optos plc (LSE: OPTS), a leading medical technology company for the design, development, manufacturing and marketing of retinal imaging devices, today announced it has entered into a Licence Agreement (“the Agreement”) with the University of Rochester (Rochester, NY) that provides the Company with exclusive access to certain patents for using adaptive optics to...
LONDON, 28 September 2006 – Optos plc (LSE: OPTS), a leading medical technology company for the design, development, manufacturing and marketing of retinal imaging devices, is today providing a pre-close trading update ahead of its preliminary results announcement on 30 November 2006.
LONDON, UK, 15 September 2006 – Optos plc (LSE: OPTS), a leading medical technology company for the design, development, manufacturing and marketing of retinal imaging devices, today announced that Stephane Sallmard has taken the decision to step down as CEO and Director of the Company with effect from 30 September 2006 and that Allan Watson, CFO, will assume the role of CEO on an interim basis....
LONDON, UK, 31 August 2006 – Optos plc (LSE: OPTS), a leading medical technology company for the design, development, manufacturing and marketing of retinal imaging devices, today announced that it will be presenting at the upcoming Goldman Sachs European Medtech & Healthcare Services Conference in London, UK, on 06-07 September 2006.
LONDON, 28 July 2006 – Optos plc (LSE: OPTS), a leading medical technology company for the design, development, manufacturing and marketing of retinal imaging devices, today announced it has entered into an agreement with LensCrafters Inc., a leading US-based optical retail chain, where 60 of the optometric practices connected with the 1, 200 retail locations owned by LensCrafters and its...
LONDON, UK, 08 June 2006 – Optos plc (LSE: OPTS), a leading medical technology company for the design, development, manufacturing and marketing of retinal imaging devices, today announced that the Company will be presenting at the Goldman Sachs 27th Annual Global Healthcare Conference being held in Dana Point, California, USA.
LONDON, UK, 07 June 2006 – Optos plc (LSE: OPTS) ('Optos' or 'the Company'), a leading medical technology company for the design, development, manufacturing and marketing of retinal imaging devices, has won the UK’s most prestigious engineering innovation accolade – The Royal Academy of Engineering 2006 MacRobert Award.
LONDON, 25 May 2006 – Optos plc (LSE: OPTS), a leading medical technology company for the design, development, manufacturing and marketing of retinal imaging devices, today announced its interim results for the six months ended 31 March 2006. Optos’ results are its first to be reported since its flotation and admission to trading on the Main Market of the London Stock Exchange on 15 February 2006.
LONDON, 19 May 2006 – Optos plc (LSE:OPTS) (‘Optos’ or the ‘Company’), a leading medical technology company for the design, development, manufacturing and marketing of retinal imaging devices, will be announcing its interim results for the six month period ended 31 March 2006 on Thursday 25 May 2006.
LONDON, 08 May 2006 – Optos plc (LSE: OPTS) ('Optos' or the 'Company'), a leading medical technology company for the design, development, manufacturing and marketing of retinal imaging devices, today announced the appointment made on Friday 05 May 2006 of Dr David R. Guyer to the Board as a non-executive director of the Company.
LONDON, 05 April 2006 – Optos plc (LSE: OPTS), a leading medical technology company for the design, development, manufacturing and marketing of retinal imaging devices, today is updating the market ahead of entering its pre-close period for the six-month period ended 31 March 2006. The Group will announce its interim results on 25 May 2006.
LONDON, 23 March 2006 – Optos plc (LSE: OPTS), a leading medical technology company for the design, development, manufacturing and marketing of retinal imaging devices, today announced that it has received clearance from the US Food & Drug Administration (FDA) under Section 510(k) of the Federal Food, Drug and Cosmetic Act (Act) to market its P200MA medical device in the United States of America,...
LONDON, 17 March 2006 – Optos plc (LSE: OPTS), a leading medical technology company for the design, development, manufacturing and marketing of retinal imaging devices today announced that OptiCare Eye Health & Vision Centers Inc., a wholly-owned subsidiary of Refac Optical Group (AMEX:REF), has installed Optos’ Panoramic200 Scanning Laser Ophthalmoscope (P200) in each of its 18 eye-care...
Optos CEO and CFO will present at Goldman Sachs European Med Tech and Healthcare Services Field Trip, London 28 March 2006
On 15 February 2006 Optos Chief Executive Officer Stephane Sallmard and Chief Financial Officer Allan Watson opened the London Stock Exchange to celebrate Optos’ admission and first day of unconditional trading of Optos shares on the LSE.
Dunfermline, Scotland, December 13, 2005 – Optos plc today announced its 2000th global customer to install its platform Panoramic200 (P200) retinal imaging device which produces the Optomap® Retinal Exam – Dr. Udo Rothe in Würzburg, Germany. Optos is a leading medical technology company for the design, development manufacture and marketing of retinal imaging devices. The P200 is the world’s first...
DUNFERMLINE, SCOTLAND – December 5, 2005 – The World Economic Forum today announced 36 Technology Pioneers for 2006. Optos plc has been selected as one of these Technology Pioneers.